Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07815886 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Benralizumab Effectiveness in EGPA

Study acronym: BELONG-EGPA
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This is a multicenter, retro-prospective observational study evaluating the effectiveness and safety of benralizumab in adult patients with eosinophilic granulomatosis with polyangiitis (EGPA) in a real-world setting. The study will include patients treated with benralizumab 30 mg every 4 weeks at EGPA referral centers participating in the European EGPA Study Group. Clinical, laboratory, lung function, treatment, relapse, and safety data will be collected from medical charts at baseline and during follow-up up to 24 months.
Trial Details
NCT Number NCT07815886
Lead Sponsor European EGPA Study Group
Conditions
(from sponsor)		 Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Related terms Churg-Strauss Syndrome, Vasculitis
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov